Regadenoson Patent Expiration
Regadenoson is Used for cardiac imaging and increasing coronary blood flow. It was first introduced by Astellas Pharma Us Inc
Regadenoson Patents
Given below is the list of patents protecting Regadenoson, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lexiscan | US8106183 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | Feb 02, 2027 | Astellas |
| Lexiscan | US9085601 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | Feb 02, 2027 | Astellas |
| Lexiscan | USRE47301 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | Feb 02, 2027 | Astellas |
| Lexiscan | US6403567 | N-pyrazole A2A adenosine receptor agonists |
Apr 10, 2022
(Expired) | Astellas |
| Lexiscan | US6642210 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7144872 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7183264 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7582617 | Myocardial perfusion imaging method |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7655636 | Use of A2A adenosine receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7655637 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7683037 | Myocardial perfusion imaging method |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8106029 | Use of A2A adenosine receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8133879 | Myocardial perfusion imaging methods and compositions |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8183226 | Myocardial perfusion imaging method |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8470801 | Myocardial perfusion imaging methods and compositions |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8536150 | Methods of myocardial perfusion imaging |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US9045519 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US9289446 | Myocardial perfusion imaging methods and compositions |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | USRE47351 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
Regadenoson's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Regadenoson:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | Indiana University | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | GE Healthcare | NA |
RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |